Ariad Blood-Cancer Drug’s 46 Percent Success Rate May Prompt FDA Approval Boost

Ariad Pharmaceuticals’ experimental drug ponatinib spurred a positive response in 47 percent of chronic myeloid leukemia patients, a pivotal study the company said may help the medicine gain approval as a new therapy for people without treatment options.
Bloomberg